Inegy

Simvastatin and ezetimibe, the active ingredients in Inegy, are a statin and a cholesterol absorption inhibitor presented as oral tablets for oral use. They are prescribed to lower elevated LDL‑cholesterol and reduce cardiovascular risk in patients with hypercholesterolemia or mixed dyslipidaemia. GNH USA supplies Inegy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inegy is used to manage lipid disorders and lower cardiovascular risk by targeting cholesterol synthesis and absorption. - Hypercholesterolemia: reduces LDL‑cholesterol levels and helps achieve target lipid profiles. - Mixed dyslipidemia: lowers both LDL‑cholesterol and triglycerides while modestly raising HDL‑cholesterol. - High‑risk cardiovascular prevention: decreases the incidence of major cardiovascular events in patients with established risk factors.

Inegy may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Myalgia: muscle aches without weakness, usually dose‑related. - Gastrointestinal discomfort: includes abdominal pain, nausea, or diarrhea. - Elevated liver enzymes: mild increases in ALT/AST observed in routine monitoring. - Fatigue: general tiredness reported by some patients.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with risk of renal failure; requires immediate medical attention. - Severe hepatic injury: marked elevation of liver enzymes or jaundice. - Allergic reactions: rash, pruritus, or angioedema. - Myopathy with marked CK elevation: muscle weakness with high creatine kinase levels. - Pancreatitis: acute abdominal pain with elevated pancreatic enzymes.

Before initiating therapy with Inegy, consider the following precautions. - Liver function monitoring: obtain baseline ALT/AST and repeat periodically during treatment. - Muscle symptom vigilance: advise patients to report unexplained muscle pain, tenderness, or weakness promptly. - Drug interaction awareness: avoid concomitant use of strong CYP3A4 inhibitors and other lipid‑lowering agents that increase myopathy risk. - Pregnancy and lactation: contraindicated in pregnancy; assess risks versus benefits if breastfeeding. - Renal impairment: dose adjustment may be required in patients with severe renal dysfunction. - Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Inegy can interact with several medications, affecting its safety and efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): may increase simvastatin exposure and risk of myopathy. - Gemfibrozil: synergistic increase in muscle toxicity. - Niacin at high doses: heightened risk of hepatotoxicity. - Cyclosporine: elevates plasma concentrations of both components.

Moderate Interactions (Monitor Closely): - Amiodarone: may modestly raise simvastatin levels. - Warfarin: potential alteration of INR, requiring closer monitoring. - Digoxin: possible increase in serum digoxin concentrations. - Antacids containing aluminum or magnesium: may reduce ezetimibe absorption. - Grapefruit juice: can modestly increase simvastatin exposure.